Amalgamated Bank Verastem, Inc. Transaction History

Amalgamated Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.83 $28,718 - $51,523	-28,155 Closed	0 $0
Q1 2022 Jun 30, 2022	SELL	$1.06 - $2.1 $2,413 - $4,781	-2,277 Reduced 7.48%	28,155 $40,000
Q4 2021 Feb 15, 2022	SELL	$2.05 - $3.2 $674 - $1,052	-329 Reduced 1.07%	30,432 $62,000
Q3 2021 Oct 29, 2021	SELL	$2.54 - $4.07 $4,551 - $7,293	-1,792 Reduced 5.5%	30,761 $95,000
Q2 2021 Aug 16, 2021	BUY	$2.57 - $4.85 $34,353 - $64,829	13,367 Added 69.67%	32,553 $132,000
Q3 2020 Oct 30, 2020	BUY	$1.11 - $1.68 $287 - $435	259 Added 1.37%	19,186 $23,000
Q2 2020 Aug 10, 2020	BUY	$1.69 - $4.2 $31,986 - $79,493	18,927 New	18,927 $33,000
Q2 2019 Aug 14, 2019	SELL	$1.25 - $3.14 $13,396 - $33,651	-10,717 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.79 - $4.09 $973 - $1,427	349 Added 3.37%	10,717 $32,000
Q4 2018 Feb 15, 2019	BUY	$3.23 - $7.01 $33,488 - $72,679	10,368 New	10,368 $35,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $840M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.